17α-Methyl-19-norprogesterone (developmental code name H-3510), also known as 17α-methyl-19-norpregn-4-ene-3,20-dione, is a progestin which was never marketed. It is a

derivative In mathematics, the derivative of a function of a real variable measures the sensitivity to change of the function value (output value) with respect to a change in its argument (input value). Derivatives are a fundamental tool of calculus. ...

of progesterone, and is the combined derivative of

17α-methylprogesterone 17α-Methylprogesterone (17α-MP), or 17α-methylpregn-4-ene-3,20-dione, is a steroidal progestin related to progesterone that was synthesized and characterized in 1949 but was never marketed.Plattner, Pl A., H. Heusser, and P. Th Herzig. "* UBE ...

and 19-norprogesterone. The drug is the

parent compound In chemistry, a parent structure is the structure of an unadorned ion or molecule from which derivatives can be visualized. Parent structures underpin systematic nomenclature and facilitate classification. Fundamental parent structures have on ...

of a subgroup of the 19-norprogesterone group of progestins, which includes demegestone (the δ⁹ derivative),

promegestone Promegestone, sold under the brand name Surgestone, is a progestin medication which is used in menopausal hormone therapy and in the treatment of gynecological disorders. It is taken by mouth. Side effects of promegestone include menstrual ...

(the δ⁹ and 21-methyl derivative), and

trimegestone Trimegestone, sold under the brand names Ondeva and Totelle among others, is a progestin medication which is used in menopausal hormone therapy and in the prevention of postmenopausal osteoporosis. It was also under development for use in birth ...

(the δ⁹, 21-methyl, and 21-hydroxyl derivative).

References

Abandoned drugs Diketones Norpregnanes Progestogens {{Genito-urinary-drug-stub

See also

References